Boehringer Ingelheim launches its first-in-class broad-spectrum topical parasite treatment for cats

NexGard® COMBO for cats is a one-and-done, easy-to-use formula with the eprinomectin, praziquantel and next-generation active antiparasitic ingredient: esafoxolaner, which has been specially formulated for cats.

Boehringer Ingelheim, a global leader in animal health, has launched the parasite treatment, NexGard® COMBO for cats. With nearly 20 years of expertise in preventing parasites such as fleas, ticks, Lyme disease and more in dogs, NexGard® now adds a feline-specific product to the NexGard® family. The new treatment is designed to safeguard cats from a wider range of parasites than any other product on the market, covering both external parasites and internal parasites such as fleas, ticks, ear mites, face mange, hookworm, roundworm, vesical worm, lungworm, heartworm prevention, as well as tapeworm infections that affect their health and quality of life. 

Boehringer Ingelheim Philippines is awarded Top Employer for the 5th year in a row

Boehringer Ingelheim is one of 15 global Top Employers worldwide

Achieved Global Recognition and Top Employer Certification in 29 countries From Top Employers Institute® 

Outstanding employer benefits with emphasis on wellbeing, attractive work environment, and rewards and recognition 

Boehringer Ingelheim (Philippines) Inc. is awarded Top Employer for the 5th year in a row.

Boehringer Ingelheim progresses toward sustainability goals through key initiatives across ASEAN, South Korea, Australia, and New Zealand

Strengthening network of stroke-ready hospitals and stroke centers to serve more than 300,000 patients including in the Philippines

Partnering with Global Alliance for Rabies Control (GARC) and community partners to vaccinate 12,000 dogs and cats across the Philippines, Indonesia, Malaysia, and Vietnam in 2022

Empowering employees and social entrepreneurs to pilot and scale accessible health solutions through its signature ‘Making More Health’ flagship initiative

Committing to carbon neutrality in company operations by 2030 (Scope 1 and 2), reducing operational waste, and eliminating single-use plastic

Boehringer Ingelheim is strengthening its commitment to positively impact people, animals, communities, and the planet through key sustainability initiatives in the Philippines and across ASEAN, South Korea, Australia, and New Zealand (ASKAN). 

Under the ‘Sustainable Development – For Generations’ framework, Boehringer Ingelheim has globally pledged EUR 250 million to combat infectious diseases in humans and animals, expanding healthcare access for non-communicable diseases for 50 million people in vulnerable communities, including in the ASKAN area, and invest EUR 35 billion in health innovation to tackle non-communicable diseases. In addition to improving access to healthcare, Boehringer Ingelheim is committed to carbon neutrality in company operations by 2030 (Scope 1 and 2) and is taking steps to contribute to food security and safety, building a sustainable and healthy future for all.